ClinicalTrials.gg
Active, not recruitingNCT03093961Updated Feb 6, 2024

REDUCE LAP-HFREF TRIAL

An interventional study of IASD implant in Heart Failure, sponsored by Corvia Medical. Active, not recruiting at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-06.

Sponsored by Corvia Medical · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 167 studies in Heart Failure with a site in Australia — 25 open to participants now, 41 under way, 9 of them phase 3. Heart Failure · Australia.

Planned enrollment
126th of 135
10 · median 350
Started
2017
with 7 others
No phase
57 of 167
14 open now
Primary completion
2026-12
later than 18 of 40 live
Registered
102nd of 167
by date
Lead sponsor
6 of 167
Corvia Medical

Among the 167 studies in Heart Failure with a site in Australia, this one is the 126th largest by planned enrollment of the 135 interventional ones that give a count, is one of 8 that started in 2017, is one of 57 with no phase, reaches primary completion later than 18 of the 40 other live ones, and was the 102nd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

25 of the 167 studies in Heart Failure with a site in Australia are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 167 studies in Heart Failure with a site in Australia, or all of them as a file.
02

Study summary

The objective of this pilot study is to evaluate the safety and performance of implanting the IASD® System II in Heart Failure patients with reduced ejection fraction and elevated left sided filling pressures, who remain symptomatic despite Guideline Directed Medical Therapy (GDMT).

Read the detailed description

The intended clinical indication of the IASD System II is the reduction of elevated LAP in patients with symptomatic heart failure with reduced ejection fraction, despite appropriate medical management. The implant is designed with a center barrel opening that, in the setting of elevated LAP, allows left to right flow. Since many of the symptoms these patients experience are believed to be due to elevated LAP, the IASD System II has the potential to significantly reduce symptoms and improve the quality of life in patients with otherwise limited treatment options.

The study design is a prospective, non-randomized, single-arm feasibility trial. This study will implant up to 10 subjects. The population will include heart failure patients with reduced ejection fraction, and elevated left sided filling pressures, who remain symptomatic despite GDMT, including optimal doses of recommended pharmaceutical treatments, surgical, and device intervention(s) (CRT, AICD, reduction of MRI). After analysis of the 1 month results (including baseline and 1 month Core laboratory echocardiographic and hemodynamic data) of the first 5 implanted patients, a decision will be made to implant an additional 5 patients,

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chronic symptomatic Heart Failure (HF) documented by the following:

    1. (NYHA) Class III/ambulatory class IV symptoms (Paroxysmal nocturnal dyspnea, Orthopnea, Dyspnea on mild or moderate exertion) at screening visit, and signs (e.g. any rales post cough, Chest x-ray demonstrating pulmonary congestion,) within past 12 months; AND
    2. One hospital admission for which HF was a major component of the hospitalization within the 12 months prior to study entry (transient heart failure in the context of myocardial infarction does not qualify), or one emergency department visit with IV treatment for HF within the 12 months prior to study entry
  2. Ongoing stable GDMT for HF (Class I, and IIa recommendations) according to the 2016 ACC/AHA Guidelines for the management of Heart Failure (with no significant changes [>100% increase or 50% decrease], excluding diuretic dose changes for a minimum of 3 months prior to screening), which is expected to be maintained without change for 6 months
  3. Age ≥ 18 years old
  4. Reduced between 20% and 40% as documented by echocardiography, radio nuclide ventriculography, or MRI within the past 3 months
  5. Elevated left atrial pressure with a gradient compared to right atrial pressure (RAP) documented by:

    a. Resting end expiratory PCWP ≥ 18 mmHg, and greater than RAP by ≥ 5 mmHg

  6. Subject has been informed of the nature of the study, agrees to its provisions and has provided written , as approved by the IRB
  7. Subject is willing to comply with clinical investigation procedures and agrees to return for all required follow-up visits, tests, and exams
  8. Trans-septal catheterization by femoral vein access is determined to be feasible

Exclusion criteria

Exclusion Criteria:

  1. Patients who are not receiving GDMT for specified reasons
  2. NT-Pro BNP \< 100 pg/mL (if in sinus rhythm), or \<300 pg/mL (if in atrial fibrillation); or BNP \< 70 pg/mL (if in sinus rhythm), or \< 200 pg/mL (if in atrial fibrillation)
  3. Myocardial infarction (MI) and/or percutaneous cardiac intervention within past 3 months; CABG in past 3 months, or current indication for coronary revascularization
  4. Cardiac Resynchronization Therapy initiated within the past 3 months
  5. Automated Implantable Cardioverter Defibrillator (AICD) placed within past 3 months
  6. Severe heart failure defined by all of the following:

    1. ACC/AHA/ESC Stage D heart failure, Non-ambulatory Class IV HF;
    2. Cardiac Index \< 2.0 L/min/m2
    3. Requiring inotropic infusion (continuous or intermittent) within the past 3 months.
    4. Listed on transplant waiting list
  7. Ability to perform the 6 minute walk Test >600m
  8. Known un-revascularized coronary artery disease, defined as: epi-cardial coronary artery stenosis associated with angina or other evidence of coronary ischemia.
  9. History of stroke, (TIA), deep vein thrombosis (DVT), or pulmonary emboli within the past 6 months or recurrent DVT/pulmonary emboli
  10. Presence of significant valve disease defined by echocardiography as:

    1. Mitral valve regurgitation defined as grade > 2+ MR
    2. Tricuspid valve regurgitation defined as grade > 2+ TR;
    3. Aortic valve disease defined as ≥ 2+ AR or moderate AS
  11. Subject is to receive either dual antiplatelet therapy or warfarin analogue; or has a documented coagulopathy
  12. Atrial fibrillation with resting HR > 100 BPM
  13. Arterial Oxygen saturation \< 95% on room air
  14. Significant hepatic impairment defined as 3X of transaminases, total , or alkaline phosphatase; Hepatic cirrhosis; Hypoalbuminemia
  15. Resting RAP > 14 mmHg
  16. Right ventricular dysfunction, defined as

    1. More than mild RV dysfunction as determined by TTE: OR
    2. TAPSE \< 1.4 cm: OR
    3. RV volume ≥ LV volume on echo estimate; OR
    4. Evidence of RV dysfunction defined by echo as an RV fractional area change \< 35%
  17. Evidence of pulmonary hypertension with PVR ≥4 Woods Units
  18. Chronic pulmonary disease requiring continuous home oxygen, OR significant chronic pulmonary disease defined as \<1L.
  19. Currently participating in an drug or device study that may interfere with the conduct and outcome of this study.
  20. less than 12 months for non-cardiovascular reasons
  21. Echocardiographic evidence of intra-cardiac mass, thrombus or vegetation
  22. Known or suspected allergy to nickel
  23. Women of child bearing potential
  24. Currently requiring dialysis; or e- \<25ml/min
  25. Systolic blood pressure >170 mmHg despite appropriate medical management
  26. Subjects with existing or surgically closed (with a patch) Atrial Septal Defects. Subjects with a Patent Foramen Ovale (PFO), who have elevated filling pressure despite the PFO are allowed
  27. Subjects on or systemic treatment
  28. In the opinion of the investigator, the subject is not an appropriate candidate for the study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Intervention

    IASD Implantation

    Device: IASD implant

Interventions

  • DeviceIASD implant

    Single arm for implant

06

What researchers measure

Primary outcomes

  1. The percent of subjects who experience major adverse cardiac and/or cerebrovascular events (MACCE)

    The primary endpoint will be peri-procedural, and 6 months Major Adverse Cardiac and Cerebrovascular Events (MACCE) and systemic embolic events in patients implanted with the IASD.

    Time frame: 6 months

  2. The percent of subjects who have successful device implantation

    Deployment at the intended location during the index procedure

    Time frame: Index Procedure

  3. The percent of subjects left to right flow through the device

    Left to right flow through the device at 6 months as assessed by an echocardiographic core laboratory

    Time frame: 6 months

07

Study locations

4 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2017 (actual). Primary completion is estimated for Dec 2026, 117 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 117 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2017
First posted
Mar 28, 2017
StartActual
Mar 10, 2017
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Feb 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03093961
Lead sponsor
Corvia Medical
Responsible party
Sponsor
First posted
Mar 28, 2017
Start date
Mar 10, 2017
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 6, 2024

Study contacts

Jan Komtebedde, DVM
study director · Corvia Medical

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion